
|Podcasts|May 10, 2023
The Latest Data for Ruxolitinib Cream in Vitiligo: Finding Context from the Outcomes
Author(s)HCP Live Staff
Listen
0:00 / 0:00
Dermatologists Raj Chovatiya, MD, PhD, and David Rosmarin, MD, discuss new research outcomes for the topical JAK inhibitor live from the Revolutionizing Atopic Dermatiti 2023 Annual Meeting in Washington, DC.
Advertisement
David Rosmarin, MD, chair of the department of dermatology at Indiana University School of Medicine, joins Raj Chovatiya, MD, PhD, to review recent long-term extension data from the phase 3 TRuE-V clinical program, as well as what is expected next in ruxolitinib cream assessment for vitiligo.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes
2
Does Artificial Intelligence Worsen Health Care Disparities?
3
Bringing Bronchiectasis Guidelines Into Everyday Practice
4
Adverse Pregnancy Outcomes as a Predictor of Cardiovascular Disease Mortality
5







































































